COMMUNIQUÉS West-GlobeNewswire

Press Release: Sanofi completes acquisition of Vicebio
04/12/2025
Sanofi completes acquisition of Vicebio Paris, December 4, 2025 . Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”) . This acquisition brings an early-stage combination vaccine candidate for [...]
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio
04/12/2025
Sanofi finalise l’acquisition de Vicebio Paris, le 4 décembre 2025 . Sanofi annonce aujourd’hui la finalisation de l’acquistion de Vicebio Ltd (« Vicebio ») . Cette acquisition apporte à Sanofi un candidat-vaccin [...]
DOGP Moves to Nearly Double DOG Token Holdings Through Strategic Agreement
04/12/2025
“Expanding Participation in a Digital Ecosystem With Real-World Utility” Mesquite, NV, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Mesquite, NV December 4, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP) today announced that its [...]
Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing
04/12/2025
San Diego, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003 , the company’s intravenous (IV) Deciparticle ™ [...]
Laigo Bio raises €11.5 million in seed financing to advance its SureTAC™ targeted protein degradation candidates in oncology and auto-immunity
04/12/2025
Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as CEO Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling [...]
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
04/12/2025
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and pronounced treatment [...]
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
04/12/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Changes to Tecan’s Board of Directors proposed to shareholders at the upcoming Annual General Meeting 2026
04/12/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Männedorf, Switzerland, December 4, 2025 – Tecan Group Ltd. (SIX Swiss Exchange: TECN) today announced that the Board of Directors [...]
Bestselling Author and Entrepreneur Dr. Reza Zahedi Expands into U.S. Market, Aiming to Build a Leading Real Estate and Media Portfolio
04/12/2025
Leadtainment founder and USA Today bestselling author announces bold U.S. expansion strategy, aiming to build a multi-million-dollar portfolio and deepen ties with key brokers, investors, and media partners. Photo [...]
The Hemp Doctor Introduces THCA Flower Subscription Box — Monthly Curated Rotating Strains, Pre-Rolls & Extras
04/12/2025
MOORESVILLE, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, one of America’s leading hemp brands, announces the launch of its Fresh Bloom THCA Flower Subscription Box —delivering a curated monthly lineup of [...]
Hapbee Appoints Hasan Shahid to Board of Directors to Strengthen Capital Markets & Strategic Growth Capabilities
04/12/2025
Seasoned technologist, investor, and capital markets leader joins Hapbee’s Board VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies, Inc. (TSXV: HAPB ; OTCQB: HAPBF ; FWB: HA1 ) (“ Hapbee [...]
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
04/12/2025
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function [...]
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
04/12/2025
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 [...]
Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering
04/12/2025
Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair [...]
Mesoblast Participation at Piper Sandler Conference
04/12/2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37 [...]
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
04/12/2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early [...]
Mesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026
03/12/2025
LAKEWOOD, Colo., Dec. 03, 2025 (GLOBE NEWSWIRE) -- - Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern [...]
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
03/12/2025
Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Consistent results across [...]
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting
03/12/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN [...]

Pages